Resources Repository
-
ReportPublication 2016Modeling to Inform Strategies to Improve Population Health
This workshop report summarizes a workshop convened by the Institute of Medicine to explore the potential …
This workshop report summarizes a workshop convened by the Institute of Medicine to explore the potential uses of simulation and other types of modeling for improving health. Participants worked to identify how modeling could inform population health decision making (selecting and refining potential strategies, ranging from interventions to investments) based on lessons learned from models that have been, or have not been, used successfully, opportunities and barriers to incorporating models into decision making, and data needs and…
State-Transition | Health/Medicine | Business/Industry | Environmental Health | Mathematical Models | Microsimulation | Dynamic Simulation | Decision Analysis | Chronic Disease/Risk | Health Systems | Policy/Regulation | Climate/Environment | Government/Law | North America -
ReportPublication 2015Opioid Dependence: Final Report
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value …
This report from the Institute for Clinical and Economic Review (ICER) examines the comparative effectiveness and value of interventions for the management of opioid dependence. The goals of the report are to document the federal and New England state regulations affecting treatment options, provide an overview of existing clinical guidelines and payer coverage policies, and summarize the evidence on the different management approaches for opioid dependence, including special considerations for adolescents. An appendix is provided by ICER.…
Technology Assessment | Health/Medicine | Business/Industry | Mental Health | Preferences/Values | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health Systems | Policy/Regulation | Government/Law | Science/Technology | North America -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Technology Assessment | Health/Medicine | Business/Industry | Environmental Health | Priority Setting/Ethics | Evidence Synthesis | Mathematical Models | Health Systems | Policy/Regulation | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | North America -
ReviewPublication 2017Model-Based Economic Evaluation of Treatments for Depression: A Systematic Review
This article, published in Pharmacoeconomics, systematically reviews the literature in order to identify model-based studies …
This article, published in Pharmacoeconomics, systematically reviews the literature in order to identify model-based studies evaluating the cost-effectiveness of treatments for depression and examine the appropriateness of different modelling technique for simulating the natural course of depression. The review yielded 41 model-based studies, of which 21 used decision trees (DTs), 15 used cohort-based state-transition Markov models (CMMs), two used individual-based state-transition models (ISMs), and three used discrete-event simulation (DES) models. Just over half of the…
State-Transition | Health/Medicine | Mental Health | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis -
ArticlePublication 2016Cost-Effectiveness of Collaborative Care for Depression and Comorbid Diabetes or CVD
This article, published in BMJ Open, presents an economic model that combines a decision tree …
This article, published in BMJ Open, presents an economic model that combines a decision tree and a Markov cohort model to investigate the long-term cost-effectiveness of collaborative care versus usual care for individuals with depression and comorbid diabetes and/or cardiovascular disease. Data from the COINCIDE trial informs the model input parameters. The COINCIDE trial is a randomized controlled trial of collaborative care versus usual care that enrolled 387 participants from 36 primary care general practices…
State-Transition | Health/Medicine | Mental Health | Cost-Effectiveness Analysis | Chronic Disease/Risk | Europe -
ReviewPublication 2016Economic Dimensions of Noncommunicable Diseases in Latin America and the Caribbean
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases …
This companion volume to Disease Control Priorities, Third Edition (DCP3), explores the impact of noncommunicable diseases (NCDs) on development and economic growth in the countries of Latin America and the Caribbean (LAC). This collection of manuscripts examines the complex interplay among NCDs, health expenditures and financial investments in health, poverty, and inequities, using up-to-date information and evidence from the LAC region. There is compelling proof that NCDs are a major and growing problem for low- and…
Technology Assessment | Health/Medicine | Mental Health | Priority Setting/Ethics | Costing Methods | Cost-Effectiveness Analysis | Child/Nutrition | Chronic Disease/Risk | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Food/Agriculture | Latin America & Caribbean -
ReviewPublication 2016Choosing an Epidemiological Model Structure for Economic Evaluation
This review presents a taxonomy of epidemiological model structures and applies it to the economic …
This review presents a taxonomy of epidemiological model structures and applies it to the economic evaluation of public health interventions for non-communicable diseases. Growing pressures on health services and on social care have led to a greater need for prevention of chronic diseases. In order for decision makers to make informed judgements about how to best spend finite public health resources, they must be able to quantify the anticipated costs, benefits, and opportunity costs of…
State-Transition | Health/Medicine | Environmental Health | Mathematical Models | Dynamic Transmission | Microsimulation | Dynamic Simulation | Chronic Disease/Risk | Social Determinants | Health Systems | Climate/Environment | Culture/Society -
ReportPublication 2015Modeling to Improve Policy Decisions in the Americas: Noncommunicable Diseases
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only …
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only to human health, but also to a country’s economic development and growth. The evidence on both of these counts is compelling. In 2012, cardiovascular disease, diabetes, cancers, chronic respiratory conditions including asthma, and other NCDs were the cause of 4.5 million deaths in the Americas. Of that total number, 1.5 million of them were premature, occurring among people aged 30-69…
State-Transition | Health/Medicine | Mental Health | Priority Setting/Ethics | Costing Methods | Mathematical Models | Microsimulation | Decision Analysis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Latin America & Caribbean -
ArticlePublication 2014Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness …
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness of alternate sequences of treatment strategies using second-generation antipsychotics (SGAs) for patients with schizophrenia. First-line treatments include one of the four SGAs: olanzapine (OLZ), risperidone (RSP), quetiapine (QTP), and ziprasidone (ZSD). Patients are able switch to another of these antipsychotics as second-line therapy, and only clozapine (CLZ) is allowed as third-line treatment. Model input parameters were obtained from the Clinical…
State-Transition | Health/Medicine | Mental Health | Cost-Effectiveness Analysis | North America